Latin America Point Of Care Infectious Disease Testing Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Point-of-care infectious disease testing in Latin America covers rapid antigen, antibody, and molecular assays deployed in clinics, pharmacies, community health posts, and field settings where centralized lab capacity is limited. The market is valued at roughly $44.7 billion in 2025, expanding at about 7.0% per year, with Latin America representing a meaningful share of that growth as decentralized testing becomes embedded in national health strategies. The region's high prevalence of vector-borne and respiratory infectious diseases, combined with post-COVID investment in diagnostic capacity, anchors long-term demand.

• •Market size approximately $44.7 billion in 2025 with a 7.0% CAGR over the forecast period
• •Brazil, Mexico, Argentina, Colombia, and Chile are the largest national markets
• •Decentralized testing is increasingly integrated into primary care and pharmacy-based service models

High and persistent infectious disease burden, including dengue, Zika, chikungunya, tuberculosis, HIV, and sexually transmitted infections, is the principal demand driver across the region. Public and donor investment in primary care expansion, along with antimicrobial resistance surveillance needs, is pushing governments to adopt faster decentralized diagnostics. The COVID-19 experience normalized rapid testing in pharmacies and community settings, and ongoing supply-chain regionalization efforts are improving device availability.

• •High prevalence of endemic and emerging infectious diseases sustains testing volume
• •Post-COVID policy shifts support decentralized and pharmacy-based testing channels
• •Antimicrobial resistance monitoring and outbreak preparedness are expanding rapid test indications

The market segments by technology into rapid immunoassays, lateral flow tests, and molecular point-of-care platforms, with immunoassays dominating volume and molecular platforms driving value growth. By application, respiratory infections, HIV, hepatitis, sexually transmitted infections, and vector-borne diseases account for the largest shares. Brazil leads regional revenue, followed by Mexico and Argentina, while Andean and Central American markets show the fastest percentage growth due to lower baseline coverage.

• •Rapid immunoassays hold the largest volume share; molecular POC is the fastest-growing value segment
• •Respiratory, HIV, hepatitis, and dengue test kits are the leading application categories
• •Brazil and Mexico together account for the majority of regional market revenue

What are the recent trends and outlook?

Sample-to-result molecular platforms are moving closer to routine use in Latin American primary care as device costs gradually decline and connectivity features improve result reporting. Multiplex panels capable of detecting several pathogens from a single sample are gaining traction, particularly for respiratory and tropical disease syndromes. Over the medium term, the market is expected to benefit from continued decentralization, stronger domestic manufacturing, and integration of point-of-care data with national surveillance systems.

• •Molecular and multiplex point-of-care platforms are the fastest-evolving technology segment
• •Digital connectivity and cloud-based result reporting are becoming standard purchasing requirements
• •Regional manufacturing initiatives supported by development banks are expected to improve supply security and pricing